Targeting the DNA Damage Response in Cancer.

By Mark J. O'Connor. Molecules and Cells, 2015

1,398 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/5793c958000bbe69fa6db9428b975f3c0d54285b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

Revisiting the hallmarks of cancer. (2017, neutral): “Although not absolutely redundant, a pathway could be seen working in place of another were the latter to be defective (a concept exploited for targeting compensating pathways in repair-deficient tumors, “synthetic lethality”) [40, 41].”
Olaparib for Metastatic Castration-Resistant Prostate Cancer. (2020, neutral): “(%) 106 (65) 52 (63) 170 (66) 84 (64) Docetaxel only 74 (46) 32 (39) 115 (45) 58 (44) Cabazitaxel only 2 (1) 0 3 (1) 0 Docetaxel and cabazitaxel 29 (18) 20 (24) 51 (20) 26 (20) Paclitaxel only 1 (<1) 0 1 (<1) 0”
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action (2016, methodology): “For the TOP1 inhibitors, including the widely used camptothecin derivatives, irinotecan and topotecan (10, 51, 60), synergy with PARP inhibitors is solely due to PARP catalytic inhibition and does not require PARP trapping.”
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer (2019, neutral): “Arthralgia 14 (15) 1 (1) 6 (10) 0 5 (−7 to 16) 1 (−5 to 6)”
Deubiquitylating enzymes and drug discovery: emerging opportunities (2017, background): “One hallmark of cancer is the downregulation, loss or deregulation of certain DNA repair and DDR pathways and/or strong reliance on such pathways 66, 67 .”
ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. (2017, background): “This probably in large part explains therapeutic successes with radiotherapy and various DNA-damaging chemotherapeutics, and also contributes to the anti-cancer properties of emerging DDRenzyme inhibitors (O'Connor, 2015).”